Single-agent antitumor efficacy of a novel oral INV-25 Liver X receptor (LXR) agonist in a checkpoint-refractory mouse B16-F10 melanoma model for Oral Presentation at the 2018 AAD Meeting in San Diego

AAD San Diego 2018.JPG

Abstract entitled "Antitumor efficacy following oral INV-25 Liver X receptor (LXR) agonist monotherapy in the B16-F10 melanoma mouse model" to be presented as Oral Presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California February 16-20, 2018.

Read Here +